Supplementary Figures S1-S16 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
crossref（2024）
Supplementary Figure 1: Additional overview of screen and quality control.
Supplementary Figure 2: Combination benefit in combination-cell line pairs.
Supplementary Figure 3: Biomarkers of single agent and combination activity.
Supplementary Figure 4: Combination activity of venetoclax plus AZD5991 in AML cell lines.
Supplementary Figure 5: Combination activity by cancer type for AZD5991 + AZ3202.
Supplementary Figure 6: Venetoclax + selumetinib and AZD5991 + selumetinib activity by cancer type.
Supplementary Figure 7: Venetoclax + selumetinib and AZD5991 + selumetinib activity by cancer type.
Supplementary Figure 8: Effect of MEK1/2 plus BCL2 inhibition on cell viability in AML cells.
Supplementary Figure 9: Effect of MEK1/2 plus MCL1 inhibition on cell viability in AML cells.
Supplementary Figure 10: Cancer type selectivity of venetoclax + AZD2811.
Supplementary Figure 11: Effect of Aurora kinase B or pan Aurora kinase plus BCL2 inhibition on cell viability in DLBCL cell lines.
Supplementary Figure 12: network analysis of AZD2811 plus venetoclax biomarkers and targets, and cancer type selectivity of AZD5991 + AZD5363.
Supplementary Figure 13: Further analysis of capivasertib (AZD5363) plus AZD5991 in endometrial cell lines.
Supplementary Figure 14: Effect of pan AKT inhibition plus MCL1 inhibition on cell viability in endometrial cell lines.
Supplementary Figure 15: Further analysis of capivasertib (AZD5363) plus AZD5991 and other inhibitors in endometrial cell lines.
Supplementary Figure 16: Effect of MCL1 genetic knockdown plus pan AKT inhibition on cell viability in endometrial cancer cell lines.
